A Phase I Study of Vinblastine and Sirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Including CNS Tumors

NCT01135563 Phase 1 COMPLETED

This study is a Phase I study using vinblastine and sirolimus in patients with relapsed solid tumors including selected brain tumors and lymphoma. The investigators hypothesis is that the combination administration of weekly vinblastine and sirolimus is safe.

Details

Lead sponsor	The Hospital for Sick Children
Phase	Phase 1
Status	COMPLETED
Enrolment	14
Start date	2010-04
Completion	2012-04

Conditions

• Solid Tumors
• Central Nervous System Tumors

Interventions

• Vinblastine and Sirolimus

Primary outcomes

• Maximum tolerated dose of vinblastine in combination with sirolimus — 12 months
  Maximum tolerated dose (as defined by protocol) of vinblastine in combination with sirolimus

Countries

United States, Canada